<DOC>
	<DOCNO>NCT00458952</DOCNO>
	<brief_summary>The purpose study determine whether iobenguane I 131 safe effective patient malignant pheochromocytoma paraganglioma .</brief_summary>
	<brief_title>Phase 1 Study Iobenguane ( MIBG ) I 131 Patients With Malignant Pheochromocytoma/Paraganglioma</brief_title>
	<detailed_description>This originally design phase 1/2 study . The phase 1 patient receive small dose study drug see tumor absorb drug . If patient 's tumor absorb drug , patient receive one therapeutic dose . In phase 1 portion , study employ 3 + 3 dose escalation design . Enrollment phase 1 portion complete research believe found high dose could give patient without cause unacceptable toxicity . This dose call maximum tolerate dose ( MTD ) . Following discussion Food Drug Administration ( FDA ) occur dose escalation stage study , protocol amend conclude trial upon identification MTD . The Phase 2 safety/ efficacy stage study conduct modification primary endpoint Protocol MIP IB12B , Special Protocol Assessment Agreement FDA March 2009 .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Have diagnosis either adrenal pheochromocytoma extraadrenal paraganglioma histological confirmation OR plasmafree metanephrines 24hour urine test catecholamines/ metanephrines Disease metastatic recur follow surgery At least one measurable lesion see compute tomography ( CT ) magnetic resonance ( MR ) scan perform within 4 week prior first dose study drug At least one know tumor site also see Ultratrace iobenguane I 131 scan Provide write informed consent willing comply protocol requirement Are least 18 year age If female , childbearing potential documented history ( e.g. , tubal ligation hysterectomy ) post menopausal minimum 1 year without menses If female childbearing potential , negative serum bHCG pregnancy test within 48 hour prior receive iobenguane I 131 Females agree become pregnant male agree father child 1 year period follow therapeutic dose Ultratrace iobenguane I 131 . Both female male must use acceptable method birth control first year follow therapeutic dose Ultratrace iobenguane I 131 . Females nurse Active CNS lesion CT/MR scan within 3 month study entry New York Heart Association class IIIIV heart failure Received previous systemic radiotherapy within 6 month study entry Administered prior wholebody radiation therapy Received external beam radiotherapy great 25 percent bone marrow Administered prior chemotherapy within 30 day study entry Karnofsky performance status le 60 Platelets less 100,000/uL Absolute neutrophil count ( ANC ) less 1,500/uL Serum creatinine great 1.5 mg/dL Total bilirubin great 1.5 time upper limit normal AST/SGOT ALT/SGPT great 2.5 time upper limit normal Has receive therapeutic investigational compound and/or medical device within 30 day admission study Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or post dose followup examination Is determined Investigator patient clinically unsuitable study . Has receive medication inhibits uptake iobenguane I 131 : phenothiazine decongestant within 2 week prior enrollment ; , tricyclic antidepressant within 6 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>MIBG</keyword>
	<keyword>iobenguane</keyword>
	<keyword>iodine</keyword>
	<keyword>I 131</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>radiopharmaceutical</keyword>
	<keyword>dosimetry</keyword>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>Ultratrace</keyword>
	<keyword>carrier add</keyword>
	<keyword>metaiodobenzyl-guanidine</keyword>
</DOC>